A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus
Cancer Medicine · 2023
DOI: 10.1002/cam4.6302 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Xiaomi Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic, Thrombosis. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and aims Hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT) predicts a poor prognosis. The aim of the present study was to evaluate the efficacy and safety of using lenvatinib and camrelizumab combined with transarterial chemoembolization (TACE) to treat HCC with PVTT.
Methods
This was a single‐arm, open‐label, multicenter, and prospective study. Eligible patients with advanced HCC accompanied by PVTT were enrolled to receive TACE combined with lenvatinib and camrelizumab. The primary endpoint was progression‐free survival (PFS), while the secondary endpoints included objective response rate (ORR), disease control rate (DCR), overall survival (OS), and safety.
Results
Between April 2020 and April 2022, 69 patients were successfully enrolled. With a median follow‐up time of 17.3 months, the median age of the patient cohort was 57 years (range: 49–64 years). According to modified Response Evaluation Criteria in Solid Tumors, the ORR was 26.1% (18 partial responses [PRs]) and the DCR was 78.3% (18 PRs, 36 stable diseases [SDs]). The median PFS (mPFS) and median OS (mOS) were 9.3 and 18.2 months, respectively. And tumor number >3 was identified as an adverse risk factor for both PFS and OS. The most common adverse events across all grades included fatigue (50.7%), hypertension (46.4%), and diarrhea (43.5%). Twenty‐four patients (34.8%) experienced Grade 3 toxicity that was relieved by dose adjustment and symptomatic treatment. No treatment‐related deaths occurred.
Conclusions
TACE combined with lenvatinib and camrelizumab is a well‐tolerated modality treatment with promising efficacy for advanced HCC with PVTT.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cancer Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China.
- Department of Oncology, Beijing You'an Hospital, Capital Medical University, Beijing, China.
- Department of Interventional Radiology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Xiaomi Li
Zitieren
APA
Li, X., Ding, X., Liu, M., Wang, J., Sun, W., Teng, Y., Xu, Y., Wu, H., Li, W., Zhou, L., & Chen, J. (2023). A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. Cancer Medicine. https://doi.org/10.1002/cam4.6302
Vancouver
Li X, Ding X, Liu M, Wang J, Sun W, Teng Y, et al. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus. Cancer Medicine. 2023. doi:10.1002/cam4.6302
BibTeX
@article{Li2023,
author = {Li, Xiaomi and Ding, Xiaoyan and Liu, Mei and Wang, Jingyan and Sun, Wei and Teng, Ying and Xu, Yawen and Wu, Hongxiao and Li, Wendong and Zhou, Lin and Chen, Jinglong},
title = {A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6302}
}
EUVIMED